Skip to main content

Table 4 Health benefit results of cost-effectiveness modelling with different transition probability matrices

From: Using informative prior based on expert opinion in Bayesian estimation of the transition probability matrix in Markov modelling—an example from the cost-effectiveness analysis of the treatment of patients with predominantly negative symptoms of schizophrenia with cariprazine

  Source of the transition probability matrix
Only the clinical trial Expert opinion + clinical trial Vague prior + clinical trial
QALY cariprazine 0.7562 0.7540 0.7512
QALY risperidone 0.7302 0.7287 0.7269
QALY difference 0.0260 0.0253 0.0243